AB&B Bio-Tech-B (02627.HK) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 July 2026, covering the month ended 30 June 2026. The filing indicates no changes in authorised, issued or treasury shares during the period.

The company’s authorised share capital stayed at RMB 393.44 million, comprising 393.44 million ordinary shares with a par value of RMB 1 each. This includes 296.36 million H shares listed on the Stock Exchange and 97.08 million unlisted domestic shares.

Issued share capital mirrored the authorised structure, with 296.36 million H shares and 97.08 million domestic shares outstanding—unchanged from the prior month. The issuer held no treasury shares.

AB&B Bio-Tech-B confirmed that, as of 30 June 2026, it satisfied the Main Board’s minimum 25 percent public-float requirement for its H-share class.

The company reported no outstanding share options, warrants, convertible securities or other agreements that could dilute existing equity. The filing was signed by Executive Director Li Runxiang, affirming compliance with all applicable listing and regulatory obligations.